OncoCyte Corp expected to post a loss of 56 cents a share - Earnings Preview

Insight Molecular Diagnostics

07/08/2024 03:03

* OncoCyte Corp  OCX.OQ   OCX.O  is expected to show a fall
in
quarterly revenue when it reports  results on August 8 for the
period ending June 30 2024
    * The Irvine California-based  company is expected to report
a
31.2% decrease in revenue to $318.5 thousand from $463 thousand
a year ago, according to the mean estimate from 2 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for OncoCyte Corp is for a
loss
of 56 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for OncoCyte
Corp is
$4.38​, above​ its last closing price of $3.05. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.65       -0.67      -1.13     Missed  -69.1
 Dec. 31 2024              -1.14      -2.12     Missed  -86.5
 Jan. 1 0001   -1.00       -1.01      -0.81     Beat    19.6​
 Jun. 30 2023  -0.68       -1.30      -1.07     Beat    17.7
 ​​Mar.        -1.31       -1.84      0.40      Beat    121.7
 31 2023                                                
 Dec. 31 2022  -2.28       -1.88      -8.00     Missed  -324.6
                                                        ​
 Jan. 1 0001   -2.28       -2.26      -1.60     Beat    29.1
 Jun. 30 2022  -2.32       -2.39      -1.40     Beat    41.3
 This summary was machine generated August 7 at 02:03 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)